Advanced Gastroesophageal Junction Adenocarcinoma

15 clinical trials · Condition

Record	Firm	Date
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma (NCT05041153)	M.D. Anderson Cancer Center	2022-02-14
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery (NCT04391049)	NRG Oncology	2021-12-02
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (NCT04535401)	National Cancer Institute (NCI)	2021-08-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)	National Cancer Institute (NCI)	2021-08-09
Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC (NCT04890392)	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	2021-01-15
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma (NCT03395847)	M.D. Anderson Cancer Center	2018-02-09

Every clearance here is in the API, with alerts when new ones post.